Intersect ENT05.08.19
Intersect ENT Inc., a company dedicated to transforming care for patients with ear, nose, and throat conditions, announced that Lisa Earnhardt will be stepping down from her role as CEO on June 5, 2019 to accept another opportunity.
Kieran Gallahue, the company’s Lead Director, has been appointed Executive Chairman of the Board of Directors, effective May 7, 2019, and interim CEO, effective June 5, 2019. Earnhardt will remain a member of the Intersect ENT Board.
“It has been an honor to lead Intersect ENT the past 11 years,” said Earnhardt. “I am extremely proud of all that we have accomplished. Together we have worked with physicians to improve the lives of over 300,000 patients, and the team is laser focused on making localized drug delivery the standard of care for chronic sinusitis sufferers. I look forward to watching this exceptional team continue to deliver over the coming years.”
Gallahue said, “On behalf of the Board and entire team, I want to thank Lisa for her many contributions to our company, and wish her the best. Under her leadership, Intersect ENT has become the leader in evidence-based innovation in the ENT specialty, and I’m excited to take an expanded role during this important time for the company. I look forward to working closely with the talented Intersect ENT team as we continue to drive growth across our portfolio and deliver value for our shareholders.”
The Intersect ENT Board has initiated a search process to identify a permanent CEO and has engaged a leading executive search firm to assist with this process.
Kieran Gallahue, the company’s Lead Director, has been appointed Executive Chairman of the Board of Directors, effective May 7, 2019, and interim CEO, effective June 5, 2019. Earnhardt will remain a member of the Intersect ENT Board.
“It has been an honor to lead Intersect ENT the past 11 years,” said Earnhardt. “I am extremely proud of all that we have accomplished. Together we have worked with physicians to improve the lives of over 300,000 patients, and the team is laser focused on making localized drug delivery the standard of care for chronic sinusitis sufferers. I look forward to watching this exceptional team continue to deliver over the coming years.”
Gallahue said, “On behalf of the Board and entire team, I want to thank Lisa for her many contributions to our company, and wish her the best. Under her leadership, Intersect ENT has become the leader in evidence-based innovation in the ENT specialty, and I’m excited to take an expanded role during this important time for the company. I look forward to working closely with the talented Intersect ENT team as we continue to drive growth across our portfolio and deliver value for our shareholders.”
The Intersect ENT Board has initiated a search process to identify a permanent CEO and has engaged a leading executive search firm to assist with this process.
